ArticleHeart and vessels2026
Relationship between serum circulating Syndecan-1 levels and myocardial fibrosis and major adverse cardiovascular events in elderly patients with atrial fibrillation.
Article in Heart and vessels, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research investigated the relationship between serum Syndecan-1 levels and myocardial fibrosis (MF) and major adverse cardiovascular events (MACEs) in elderly patients with atrial fibrillation (AF). Elderly patients with AF were divided into MF (n = 162) and N-MF (n = 89) groups. During 5-year follow-up, 78 patients with MACEs formed the MACEs group, and 173 without MACEs formed the N-MACEs group. Spearman correlation analysis was performed. Multivariate Cox regression and Kaplan-Meier curves were conducted, and ROC curves were plotted. Serum Syndecan-1 was elevated in the MF group versus the N-MF group. Serum Syndecan-1 levels in AF patients showed moderate positive correlations with both sST2 (r = 0.569) and PINP (r = 0.446). Serum Syndecan-1 showed diagnostic value for MF in patients with AF, with an AUC of 0.810. Moreover, combined detection with sST2 and PINP further achieved an AUC of 0.872. Serum Syndecan-1 levels were elevated in the MACE group compared to the N-MACEs group, and serum Syndecan-1 demonstrated discriminatory value for 5-year MACEs (AUC = 0.832). Serum Syndecan-1 (HR = 1.049) was independently associated with 5-year MACEs in AF patients. The risk associated with Syndecan-1 was more pronounced in patients with paroxysmalAF. After adjusting for sST2, NT-proBNP, LVEF, and MF, Syndecan-1 was independently associated with MACEs in patients with heart failure (P = 0.021). Elevated serum Syndecan-1 levels are associated with MF and MACEs in AF patients, suggesting its potential value as a biomarker for discriminating MF and MACEs in AF patients.
Indexed as
Identifiers
42472737What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.